Philip J. Rosenthal, MD

Phillip J.Rosenthal
Global Health Sciences Faculty Affiliate

Phone: 415-206-8845
UCSF Box: 0811
Email: prosenthal@medsfgh.ucsf.edu
UCSF Profile

Project Sponsor Location(s) Topics Start End
Global Malaria Prevention and Control University of California Berkeley Uganda Malaria
Novel Tetracyclines as Antimalarial Agents Paratek Pharmaceuticals, Inc. United States Malaria, Drug and Diagnostics Development
Evaluation of Falcipain as an Antimalarial Drug Target NIH National Institute of Allergy and Infectious Disease United States Malaria
Novel Tetracyclines as Antimalarial Agents Paratek Pharmaceuticals, Inc. United States Malaria, Drug and Diagnostics Development
Development and Testing of New Medications for the Treatment of Emerging Infectious Diseases [I] University of Mississippi United States Infectious Disease, Drug and Diagnostics Development
Training In Malaria Research in Uganda NIH John F. Fogarty International Center Uganda Malaria, Training and Capacity Building
Falcipain Cysteine Proteases of Malaria Parasites NIH National Institute of Allergy and Infectious Disease United States Malaria
Development of Falcipain Inhibitors as Antimalarial Drugs Medicines for Malaria Venture United States Malaria, Drug and Diagnostics Development
A Prospective Cohort Study of the association between HIV and Malaria Incidence and Response to Antimalarial Therapy in African Children Arnold P. Gold Foundation, The Uganda HIV/AIDS, Malaria, Pediatrics
Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies NIH National Institute of Allergy and Infectious Disease Uganda Malaria
Clinical and Molecular Studies of Drug Resistant Malaria [I] NIH National Institute of Allergy and Infectious Disease Uganda Malaria
Training In Malaria Research in Uganda NIH John F. Fogarty International Center Uganda Malaria, Training and Capacity Building
Functional Outcomes in Pediatric Liver Transplantion Lurie Children's Hospital of Chicago United States Pediatrics
Development and Testing of New Medications for the Treatment of Emerging Infectious Diseases [II] University of Mississippi United States Infectious Disease, Neglected Tropical Diseases (NTDs), Malaria
Discovery of Oxaboroles as New Antimalarial Agents NIH National Institute of Allergy and Infectious Disease United States Malaria
Translational Studies of Antimalarial Drug Resistance Doris Duke Charitable Foundation Uganda Zoonosis, Emerging Disease, and Drug Resistance, Malaria
Berkeley Minority Health/Global Health (MH/GH) Training Program University of California Berkeley Kenya; Tanzania; India Training and Capacity Building
Comparison of Home-Based Management of Fever/Malaria to Enhanced Health Facility-Based Care in Tororo, Uganda London School of Hygiene & Tropical Medicine Uganda Malaria
Chemicals with Potential Activity against Malaria Parasites Pharmadyn, Inc. Malaria, Drug and Diagnostics Development
Etiology of Non-Malarial Febrile Illnesses in Ugandan Children Doris Duke Charitable Foundation Uganda Malaria, Pediatrics
Training in Malaria Research in Uganda NIH John F. Fogarty International Center Uganda Malaria, Training and Capacity Building
Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies NIH National Institute of Allergy and Infectious Disease Uganda; Burkina Faso Zoonosis, Emerging Disease, and Drug Resistance, Malaria
Discovery of benzoxaboroles for the treatment of cryptosporidiosis Anacor Pharmaceuticals, Inc. United States Infectious Disease, Drug and Diagnostics Development
Berkeley's Minority Health/Global Health Training Program University of California Berkeley United States Neglected Tropical Diseases (NTDs), HIV/AIDS, Malaria, Residencies, Fellowships, and Postdoctoral Training
Discovery of Oxaboroles as New Antimalarial Agents NIH National Institute of Allergy and Infectious Disease Uganda Malaria, Drug and Diagnostics Development
Discovery of Oxaboroles as New Antimalarial Agents NIH National Institute of Allergy and Infectious Disease United States Malaria